Emerging therapies in malignant pleural mesothelioma

Crit Rev Oncol Hematol. 2019 Dec:144:102815. doi: 10.1016/j.critrevonc.2019.102815. Epub 2019 Oct 5.


Malignant pleural mesothelioma (MPM) is a rare cancer of the pleural surfaces frequently related to asbestos exposure. It is characterized by a poor prognosis even for patients treated with trimodality therapy, including surgery, chemotherapy and radiotherapy. Moreover, the majority of patients are not candidates for surgery due to disease advanced stage or medical comorbidities. For these patients, the survival rate is even lower and few therapeutic options are currently available. Nevertheless, many interesting novel approaches are under investigation, among which immunotherapy represents one of the most promising emerging strategies. In this review, we will discuss the role of new therapeutic options, particularly immunotherapy, and present the results of the most important and promising clinical trials.

Keywords: Anti-mesothelin therapy; Antiangiogenic therapy; Immunotherapy; Malignant pleural mesothelioma; Molecular; Target therapy.

Publication types

  • Review

MeSH terms

  • Combined Modality Therapy
  • Humans
  • Immunotherapy
  • Lung Neoplasms*
  • Mesothelioma*
  • Pleural Neoplasms*